Product Sales
Full Year 2017 Product Sales
Our complementary healthcare businesses address the changing needs of patients and societies worldwide. With innovative pharmaceuticals at the core, we are also a global leader in eye care and generics products.
Read more about the 2017 sales of our top 20 pharmaceutical products in the table below.
| Brands | Net Sales (USD m) | % change (cc) | Business Franchise |
|---|---|---|---|
| Gilenya | 3,185 | 2% | Neuroscience |
| Cosentyx | 2,071 | 82% | Immunology & Dermatology |
| Gleevec/Glivec | 1,943 | -41% | Oncology |
| Lucentis | 1,888 | 4% | Ophthalmology |
| Tasigna | 1,841 | 9% | Oncology |
| Sandostatin | 1,612 | -1% | Oncology |
| Afinitor/Votubia | 1,525 | 2% | Oncology |
| Galvus | 1,233 | 5% | Established Medicines |
| Exjade/Jadenu | 1,059 | 11% | Oncology |
| Exforge | 960 | 4% | Established Medicines |
| Diovan/Co-Diovan | 957 | -9% | Established Medicines |
| Xolair1 | 920 | 11% | Respiratory |
| Tafinlar/Mekinist | 873 | 29% | Oncology |
| Promacta/Revolade | 867 | 37% | Oncology |
| Votrient | 808 | 10% | Oncology |
| Jakavi | 777 | 32% | Oncology |
| Travoprost Group | 589 | -5% | Ophthalmology |
| Entresto | 507 | 195% | Cardio-Metabolic |
| Neoral/Sandimmun(e) | 488 | -4% | Immunology & Dermatology |
| Voltaren/Cataflam | 465 | -4% | Established medicines |
- Net sales reflect Xolair sales for all indications (e.g. including Xolair SAA and Xolair CSU, which is managed by the Immunology and Dermatology franchise).